Hydroxychloroquine-d4 sulfate(Synonyms: HCQ-d4 sulfate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Hydroxychloroquine-d4 sulfate (Synonyms: HCQ-d4 sulfate)

Hydroxychloroquine-d4 sulfate (HCQ-d4 sulfate) 是 Hydroxychloroquine sulfate 的氘代物。Hydroxychloroquine (HCQ) sulfate 是一种合成的抗疟疾剂，也可以抑制 Toll 样受体 7/9 (TLR7/9) 信号传导。Hydroxychloroquine sulfate 有效抑制 SARS-CoV-2 感染。

Hydroxychloroquine-d4 sulfate(Synonyms: HCQ-d4 sulfate)

Hydroxychloroquine-d4 sulfate Chemical Structure

CAS No. : 1854126-45-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Hydroxychloroquine-d4 sulfate (HCQ-d4 sulfate) is the deuterium labeled Hydroxychloroquine sulfate. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

437.97

Formula

C18H24D4ClN3O5S
CAS 号

1854126-45-6
中文名称

硫酸羟氯喹 d4 (硫酸盐)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6.

    [3]. Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85(3):429-40.

    [4]. Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务